Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Assets (2016 - 2026)

Cumberland Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $39.8 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 1.62% to $39.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $150.5 million, a 10.9% decrease, with the full-year FY2025 number at $39.8 million, up 1.62% from a year prior.
  • Non-Current Assets hit $39.8 million in Q4 2025 for Cumberland Pharmaceuticals, up from $36.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CPIX hit a ceiling of $51.4 million in Q1 2022 and a floor of $36.0 million in Q3 2025.
  • Historically, Non-Current Assets has averaged $42.8 million across 5 years, with a median of $42.6 million in 2021.
  • Biggest five-year swings in Non-Current Assets: decreased 18.54% in 2021 and later rose 21.36% in 2022.
  • Tracing CPIX's Non-Current Assets over 5 years: stood at $38.8 million in 2021, then rose by 21.36% to $47.1 million in 2022, then dropped by 2.11% to $46.1 million in 2023, then fell by 15.05% to $39.1 million in 2024, then increased by 1.62% to $39.8 million in 2025.
  • Business Quant data shows Non-Current Assets for CPIX at $39.8 million in Q4 2025, $36.0 million in Q3 2025, and $36.7 million in Q2 2025.